Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PREDNISONE

All products: general benefit

Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable

  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit

3 more in the class list below

Teva-Prednisone · DIN 00232378 · 50mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Prednisone · DIN 00232378 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2015-06-12 · brand TEVA-PREDNISONE · ATC H02AB07 PREDNISONE · form Tablet · route Oral · ingredients PREDNISONE 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1735 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1286 · Verify on the e-Formulary ↗ (DIN 00232378)

Source record
DIN 00232378: Teva-Prednisone Raw flags: sec3=Y Item: 680400029; group id 719; item number 1777; lccId None; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.1900; ministry $0.1735 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00232378 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1286
Interchangeable products
Apo-Prednisone · DIN 00550957 · $0.1735 Deltasone · DIN 00252417 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE 68:04 Corticosteroids

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES Endocrine disorders: Primary or secondary adrenoc ortic al insufficiency (hydroc ortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineraloc ortic oids where applicable; in infancy, mineraloc orticoid supplementation is of particular importance); congenital adrenal hyperplasia; nonsuppurativ e thyroiditis ; hypercalc emia associated with cancer. Nonendocrine disorders: Rheumatic disorders: As adjunctiv e therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenanc e therapy ), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosy novitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, acute rheumatic carditis, systemic dermatomyositis (polymyositis), polymyalgia rheumatica, giant cell arthritis. Dermatologic diseases: … https://pdf.hres.ca/dpd_pm/00078427.PDF PM date: JAN 15 2025 Source product: TEVA-PREDNISONE; DIN 00021695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.